Abstract 4401
Background
In Feb 2015, palbociclib plus letrozole (P+L) became the first cyclin-dependent-kinase 4/6 inhibitor approved for mBC/aBC in the US. Until now, long-term outcomes studies have included a limited number of patients receiving P+L. The objective of this study is to describe real-world patient characteristics and clinical effectiveness associated with P+L as initial endocrine-based therapy use 4 years post approval.
Methods
Adult postmenopausal women diagnosed with metastatic HR+/HER2- breast cancer who initiated P+L as first-line therapy on or after 2/3/2015 were identified by providers in the Cardinal Health Oncology Provider Extended Network, including 1800 oncologists/hematologists in the US. A subset of providers abstracted data related to patient characteristics and clinical outcomes including disease response and disease progression into an electronic case report from (eCRF). Data were abstracted from the time of initiation of P+L through Feb 2019 (or end of follow up/death). Providers were shown response classification schema corresponding to RECIST v1.1 and asked to indicate the patient’s best response if recorded. The objective response rates (ORR – incl. complete response [CR] and partial response [PR]), clinical benefit rates (CBR – incl. CR+PR+stable disease [SD] >24 wks), and progression-free survival (PFS) rate at 12-month were reported. Each eCRF was reviewed by independent clinical staff; source data was verified on 10% of the patients.
Results
31 providers submitted 202 eCRFs, of which, 193 were eligible. Median follow-up from 1L P+L initiation was 15.4 months, 45.6% of patients had discontinued P+L at data cut-off. Table shows key patient characteristics and ORR, CBR, and PFS rate at 12-month, each showing benefit of 1L P+L in the real-world.Table:
338P
N = 193 | All |
---|---|
Mean age at diagnosis, yrs | 62.7 |
Non-Hispanic white, % | 74.6 |
Black/African-American, % | 17.1 |
ECOG-PS 0/1, % | 89.6 |
N0, % | 22.8 |
Visceral mets, % | 51.3 |
Bone only mets, % | 25.4 |
ORR, % | 65.8 |
CR | 9.8 |
PR | 56.0 |
CBR†, % | 88.0 |
CR | 12.7 |
PR | 61.3 |
SD† | 14.0 |
12-month PFS, % | 74.5 |
†Excluding 43 patients with duration of treatment <24 wks
Conclusions
These real-world data demonstrate the benefit of 1L P+L 4 years post approval in the US and support the clinical benefit of 1L P+L reported in randomized clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
J. Kish: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. J. Trocio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. T. Miller: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Nero: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Liassou: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. X. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. L. McRoy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. B. Feinberg: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc.
Resources from the same session
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract